Unique Proprietary Solutions for Your Cellular Immunotherapy Pipeline

Progenitor has developed a series of proprietary technologies for addressing problem areas within the current Immunotherapy pipeline. Current pipelines are costly, use viral integration methods or are bound in expensive IP licensing of gene editing technologies like Crisper/Cas9 and Zinc finger nucleases. Progenitor’s workflow design enables your Immunotherapy pipeline in Genomic Modification, Target Cell Traits and Therapeutic Development.